Cure My Disease

Don't miss your cure!

 Log in / Sign up

Can imaging replace the scalpel for skin cancer checks?

NCT ID NCT07803406

Knowledge-focused Sponsor: Bispebjerg Hospital Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now This study
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Sep 03, 2026 · Last updated Sep 04, 2026 · Updated 1 time

Summary

This study tests three non-invasive imaging devices on adults with basal cell carcinoma, the most common skin cancer. Researchers measure how long each scan takes, how comfortable it feels, and how well the tools work on different body areas. Participants attend one 40-minute visit and receive three skin scans, with no biopsies or invasive procedures. The goal is to see whether these imaging tools are practical for everyday skin cancer assessment.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
Non-invasive multimodal skin imaging using three AI-assisted devices: optical coherence tomography (OCT), line-field confocal optical coherence tomography (LC-OCT), and high-frequency ultrasound (HFUS)
What this could lead to
If these imaging tools prove fast and comfortable, they could become a routine way to examine skin cancers without cutting into the skin, possibly reducing the need for biopsies.
What could go wrong
This is a small observational study focused on usability, not on whether the imaging improves diagnosis or treatment. The tools may not work equally well on all skin areas or lesion types.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Participants

About 50 people

The number the study aims to enrol. It can still change while the study runs.

Expected to start

Sep 2026

An estimate. Start dates often move.

Expected to finish

Nov 2027

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Who is studied

Adults aged 18 years or older with histologically confirmed or clinically suspected basal cell carcinoma attending the Department of Dermatology, Bispebjerg Hospital, Copenhagen, Denmark, as part of their routine clinical care.

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: Age 18 years or older Presence of a histologically confirmed or clinically suspected basal cell carcinoma lesion scheduled for standard clinical management Ability to provide written informed consent Exclusion Criteria: Inability to provide informed consent

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Basal cell carcinoma of skin are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

basal cell carcinoma skin basal cell carcinoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Basal cell carcinoma of skin

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The places running it

    1 site. The list below names each one and where it is.

  2. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  3. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Locations

  • Department of Dermatology, Bispebjerg Hospital

    RECRUITING

    Copenhagen, Denmark, 2400, Denmark

More trials for these conditions

Other studies related to the condition(s) this trial covers.